Clinical characteristics associated with pulmonary function decline despite sustained nintedanib therapy in systemic autoimmune rheumatic disease–related progressive pulmonary fibrosis

Clicks: 11
ID: 331506
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #46 of 48 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: To identify clinical factors associated with pulmonary function decline despite sustained nintedanib treatment for ≥1 year in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) with progressive pulmonary fibrosis (PPF). METHODS: We retrospectively analyzed 69 patients from the KEIO-SARD-ILD cohort who initiated nintedanib. Among those who continued treatment for ≥1 year, patients were classified into Decliner (absolute decline in %FVC >5% at 12 months) and Stable groups, and clinical characteristics were compared. Independent predictors of %FVC decline were identified using multivariable logistic regression. RESULTS: Among 69 patients who initiated nintedanib, 18 (26.1%) showed a decline in %FVC >5% at 12 months. Discontinuation of nintedanib within 12 months and a UIP pattern were independently associated with %FVC decline in the overall cohort. Among patients who continued nintedanib for ≥1 year, 8 of 51 patients (15.7%) experienced %FVC decline despite sustained treatment (Decliner group). Compared with Stable group, Decliner group had significantly lower body surface area and lower eGFR. In multivariable analysis, low body surface area and chronic kidney disease were independently associated with %FVC decline. Patients with both risk factors had a significantly higher prevalence of pulmonary function decline than those without these factors. Decliner group had worse overall survival than Stable group. CONCLUSIONS: A subset of patients with SARD-ILD-related PPF experienced pulmonary function decline despite sustained nintedanib treatment. The decliner group had lower body surface area and higher prevalence of chronic kidney disease, suggesting that patients with these factors may be at increased risk of disease progression despite antifibrotic therapy.
Reference Key
openalex_W7220409923 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Koji Suzuki, Mitsuhiro Akiyama, Kanako Shimanuki, Hiroyuki Fukui, Yuko Kaneko
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag088
URL
https://doi.org/10.1093/mr/roag088
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.